Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Corbus Pharmaceuticals Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 337's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 337 underperformed the German Biotechs industry which returned -9% over the past year.
Return vs Market: 337 underperformed the German Market which returned -14.3% over the past year.
Price Volatility Vs. Market
How volatile is Corbus Pharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Corbus Pharmaceuticals Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 337 (€4.62) is trading below our estimate of fair value (€43.6)
Significantly Below Fair Value: 337 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 337 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 337 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 337's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 337 is overvalued based on its PB Ratio (54.9x) compared to the DE Biotechs industry average (3.4x).
How is Corbus Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 337 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 337 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 337 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 337's revenue (56.1% per year) is forecast to grow faster than the German market (3.9% per year).
High Growth Revenue: 337's revenue (56.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 337's Return on Equity is forecast to be high in 3 years time
How has Corbus Pharmaceuticals Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 337 is currently unprofitable.
Growing Profit Margin: 337 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 337 is unprofitable, and losses have increased over the past 5 years at a rate of -46.5% per year.
Accelerating Growth: Unable to compare 337's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 337 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.9%).
Return on Equity
High ROE: 337 has a negative Return on Equity (-1160.42%), as it is currently unprofitable.
How is Corbus Pharmaceuticals Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 337's short term assets ($38.2M) exceed its short term liabilities ($34.9M).
Long Term Liabilities: 337's short term assets ($38.2M) exceed its long term liabilities ($8.1M).
Debt to Equity History and Analysis
Debt Level: 337's debt to equity ratio (12.2%) is considered satisfactory.
Reducing Debt: 337's debt to equity ratio has increased from 2.5% to 12.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 337 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 337 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -44% each year
What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 337's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 337's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 337's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 337's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 337's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yuval Cohen (44yo)
Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc ...
CEO Compensation Analysis
Compensation vs Market: Yuval's total compensation ($USD3.57M) is above average for companies of similar size in the German market ($USD1.11M).
Compensation vs Earnings: Yuval's compensation has increased whilst the company is unprofitable.
|CEO & Director||6yrs||US$3.57m||0.098% $341.9k|
|Co-Founder & Consultant||1yr||US$1.66m||2.91% $10.1m|
|Head of Research & Chief Medical Officer||5.67yrs||US$1.69m||0.28% $991.8k|
|Chief Financial Officer||6yrs||US$1.24m||0.48% $1.7m|
|Chief Operating Officer||no data||no data||0.049% $170.7k|
|Senior Director of Investor Relations & Communications||no data||no data||no data|
|Senior Director & Head of Clinical Operations||no data||no data||no data|
|Chief Commercial Officer||1.17yrs||no data||0.017% $57.7k|
|Executive Director of Research||no data||no data||no data|
Experienced Management: 337's management team is seasoned and experienced (5.7 years average tenure).
|CEO & Director||6yrs||US$3.57m||0.098% $341.9k|
|Independent Director||5.67yrs||US$213.62k||0.065% $226.1k|
|Member of Scientific Advisory Board||4.92yrs||no data||no data|
|Member of Scientific Advisory Board||1.58yrs||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Independent Director||1.83yrs||US$325.35k||0.0014% $4.8k|
|Independent Director||1yr||no data||no data|
|Director||0.083yr||no data||no data|
Experienced Board: 337's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 337 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.1%.
Corbus Pharmaceuticals Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Corbus Pharmaceuticals Holdings, Inc.
- Ticker: 337
- Exchange: DB
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$379.125m
- Listing Market Cap: US$348.643m
- Shares outstanding: 72.49m
- Website: https://www.corbuspharma.com
Number of Employees
- Corbus Pharmaceuticals Holdings, Inc.
- 500 River Ridge Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CRBP||NasdaqGM (Nasdaq Global Market)||Yes||New Common Shares||US||USD||Oct 2014|
|337||DB (Deutsche Boerse AG)||Yes||New Common Shares||DE||EUR||Oct 2014|
|0SZI||LSE (London Stock Exchange)||Yes||New Common Shares||GB||USD||Oct 2014|
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases. In addition, it has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/08 23:44|
|End of Day Share Price||2020/04/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.